Compare BLND & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | MLYS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.7M | 3.1B |
| IPO Year | 2021 | 2023 |
| Metric | BLND | MLYS |
|---|---|---|
| Price | $3.18 | $36.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $4.80 | ★ $46.40 |
| AVG Volume (30 Days) | ★ 4.0M | 1.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,532,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.61 | N/A |
| 52 Week Low | $2.50 | $8.24 |
| 52 Week High | $5.34 | $47.65 |
| Indicator | BLND | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 40.09 |
| Support Level | $3.18 | $35.77 |
| Resistance Level | $3.40 | $44.13 |
| Average True Range (ATR) | 0.14 | 1.93 |
| MACD | 0.03 | -0.64 |
| Stochastic Oscillator | 48.89 | 14.95 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.